Phase I trial of N-(phosphonoacetyl)-L-aspartate

C. Erlichman, J. M. Strong, P. H. Wiernik, L. M. McAvoy, M. H. Cohen, A. S. Levine, S. M. Hubbard, B. A. Chabner

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A Phase I clinical trial of N-(phosphonacetyl)-L-aspartate, an antimetabolite which inhibits a key enzyme in the de novo pathway of pyrimidine biosynthesis, was conducted. N-(Phosphonacetyl)-L-aspartate was given as an i.v. 15-min infusion once daily for five days; cycles of treatment were repeated every three weeks. Thirty-four patients received treatment. Dose-limiting toxicity was observed at 1500 to 2000 mg/sq m/day and was manifested by skin rash, diarrhea, and stomatitis. Rash and diarrhea usually began during the first week of treatment and persisted up to Day 17 of a cycle of therapy. No consistent hematopoietic, hepatic, or renal toxicity was observed. One partial response in a patients with colon carcinoma was seen and continues at more than eight months. Stable disease was observed in three patients with colon carcinoma, two patients with hypernephroma. one patient with pancreatic carcinoma, and one patient with melanoma. The predictability and reversibility of toxicity and the suggestion of antitumor activity in humans are observations which support the further evaluation of N-(phosphoacetyl)-L-aspartate in Phase II studies.

Original languageEnglish (US)
Pages (from-to)3992-3995
Number of pages4
JournalCancer Research
Volume39
Issue number10
StatePublished - 1979
Externally publishedYes

Fingerprint

NSC 224131
Exanthema
Diarrhea
Colon
Carcinoma
Antimetabolites
Stomatitis
Clinical Trials, Phase I
Therapeutics
Renal Cell Carcinoma
Aspartic Acid
Human Activities
Melanoma
Kidney

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Erlichman, C., Strong, J. M., Wiernik, P. H., McAvoy, L. M., Cohen, M. H., Levine, A. S., ... Chabner, B. A. (1979). Phase I trial of N-(phosphonoacetyl)-L-aspartate. Cancer Research, 39(10), 3992-3995.

Phase I trial of N-(phosphonoacetyl)-L-aspartate. / Erlichman, C.; Strong, J. M.; Wiernik, P. H.; McAvoy, L. M.; Cohen, M. H.; Levine, A. S.; Hubbard, S. M.; Chabner, B. A.

In: Cancer Research, Vol. 39, No. 10, 1979, p. 3992-3995.

Research output: Contribution to journalArticle

Erlichman, C, Strong, JM, Wiernik, PH, McAvoy, LM, Cohen, MH, Levine, AS, Hubbard, SM & Chabner, BA 1979, 'Phase I trial of N-(phosphonoacetyl)-L-aspartate', Cancer Research, vol. 39, no. 10, pp. 3992-3995.
Erlichman C, Strong JM, Wiernik PH, McAvoy LM, Cohen MH, Levine AS et al. Phase I trial of N-(phosphonoacetyl)-L-aspartate. Cancer Research. 1979;39(10):3992-3995.
Erlichman, C. ; Strong, J. M. ; Wiernik, P. H. ; McAvoy, L. M. ; Cohen, M. H. ; Levine, A. S. ; Hubbard, S. M. ; Chabner, B. A. / Phase I trial of N-(phosphonoacetyl)-L-aspartate. In: Cancer Research. 1979 ; Vol. 39, No. 10. pp. 3992-3995.
@article{5de1748c445b4d48a445943e4ce07f9c,
title = "Phase I trial of N-(phosphonoacetyl)-L-aspartate",
abstract = "A Phase I clinical trial of N-(phosphonacetyl)-L-aspartate, an antimetabolite which inhibits a key enzyme in the de novo pathway of pyrimidine biosynthesis, was conducted. N-(Phosphonacetyl)-L-aspartate was given as an i.v. 15-min infusion once daily for five days; cycles of treatment were repeated every three weeks. Thirty-four patients received treatment. Dose-limiting toxicity was observed at 1500 to 2000 mg/sq m/day and was manifested by skin rash, diarrhea, and stomatitis. Rash and diarrhea usually began during the first week of treatment and persisted up to Day 17 of a cycle of therapy. No consistent hematopoietic, hepatic, or renal toxicity was observed. One partial response in a patients with colon carcinoma was seen and continues at more than eight months. Stable disease was observed in three patients with colon carcinoma, two patients with hypernephroma. one patient with pancreatic carcinoma, and one patient with melanoma. The predictability and reversibility of toxicity and the suggestion of antitumor activity in humans are observations which support the further evaluation of N-(phosphoacetyl)-L-aspartate in Phase II studies.",
author = "C. Erlichman and Strong, {J. M.} and Wiernik, {P. H.} and McAvoy, {L. M.} and Cohen, {M. H.} and Levine, {A. S.} and Hubbard, {S. M.} and Chabner, {B. A.}",
year = "1979",
language = "English (US)",
volume = "39",
pages = "3992--3995",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Phase I trial of N-(phosphonoacetyl)-L-aspartate

AU - Erlichman, C.

AU - Strong, J. M.

AU - Wiernik, P. H.

AU - McAvoy, L. M.

AU - Cohen, M. H.

AU - Levine, A. S.

AU - Hubbard, S. M.

AU - Chabner, B. A.

PY - 1979

Y1 - 1979

N2 - A Phase I clinical trial of N-(phosphonacetyl)-L-aspartate, an antimetabolite which inhibits a key enzyme in the de novo pathway of pyrimidine biosynthesis, was conducted. N-(Phosphonacetyl)-L-aspartate was given as an i.v. 15-min infusion once daily for five days; cycles of treatment were repeated every three weeks. Thirty-four patients received treatment. Dose-limiting toxicity was observed at 1500 to 2000 mg/sq m/day and was manifested by skin rash, diarrhea, and stomatitis. Rash and diarrhea usually began during the first week of treatment and persisted up to Day 17 of a cycle of therapy. No consistent hematopoietic, hepatic, or renal toxicity was observed. One partial response in a patients with colon carcinoma was seen and continues at more than eight months. Stable disease was observed in three patients with colon carcinoma, two patients with hypernephroma. one patient with pancreatic carcinoma, and one patient with melanoma. The predictability and reversibility of toxicity and the suggestion of antitumor activity in humans are observations which support the further evaluation of N-(phosphoacetyl)-L-aspartate in Phase II studies.

AB - A Phase I clinical trial of N-(phosphonacetyl)-L-aspartate, an antimetabolite which inhibits a key enzyme in the de novo pathway of pyrimidine biosynthesis, was conducted. N-(Phosphonacetyl)-L-aspartate was given as an i.v. 15-min infusion once daily for five days; cycles of treatment were repeated every three weeks. Thirty-four patients received treatment. Dose-limiting toxicity was observed at 1500 to 2000 mg/sq m/day and was manifested by skin rash, diarrhea, and stomatitis. Rash and diarrhea usually began during the first week of treatment and persisted up to Day 17 of a cycle of therapy. No consistent hematopoietic, hepatic, or renal toxicity was observed. One partial response in a patients with colon carcinoma was seen and continues at more than eight months. Stable disease was observed in three patients with colon carcinoma, two patients with hypernephroma. one patient with pancreatic carcinoma, and one patient with melanoma. The predictability and reversibility of toxicity and the suggestion of antitumor activity in humans are observations which support the further evaluation of N-(phosphoacetyl)-L-aspartate in Phase II studies.

UR - http://www.scopus.com/inward/record.url?scp=0018663269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018663269&partnerID=8YFLogxK

M3 - Article

C2 - 157801

AN - SCOPUS:0018663269

VL - 39

SP - 3992

EP - 3995

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -